Pharmaceutical CAS 153439-40-8 Fexofenadine Hcl Antihistaminic Fexofenadine Hydrochloride powder Purity Fexofenadine Hydrochloride
Product Description
Product Datails
| Product Name |
Fexofenadine Hydrochloride |
| CAS |
153439/40/8 |
| Appearance |
White powder |
| Molecular formula |
C5H3N3 |
| Assay |
98% |
The product is white crystalline, melting point 190-194 degree C, specific optical rotation 72.5 degree (c=2, H_2O, 5hrs.), water soluble, odorless, slightly sweet, soluble in water, slightly soluble, insoluble in organic solvents such as ethanol. Usage: mainly used for medical and pharmaceutical products. It has important physiological functions for human body, participates in detoxification of liver and kidney, plays an anti-inflammatory and liver-protecting role, stimulates the growth of Bifidobacterium in infant intestine, has good curative effect on treating rheumatic arthritis and gastric ulcer, inhibits the growth of cells, is the main raw material for synthesizing antibiotics and anticancer drugs, and can also be used in food, chemical and chemical industries. Cosmetics and feed additives are widely used.
Glucosamine hydrochloride is the only substance that can be used to treat bone and joint diseases. Glucosamine should be used with chondroitin sulfate to relieve pain and promote cartilage regeneration, which can fundamentally improve joint problems. If you can supplement vitamin D and calcium at the same time, you can get better results.
Application&Function
1.Lorcaser hcl is an FDA-approved prescription weight-loss medication that, when used with diet and exercise, can help some overweight adults with a weight-related medical problem, or obese adults, lose weight and keep it off.
2.Lorcaser hydrochlorideis a serotonin 2C receptor agonist. It hasbeen shown to decrease food consumption and promote sa tiety by selectivelyactivating serotonin 2C receptors in the brain.
3.Lorcaser hcl is specifically indicated as an adjunct to a reduced-calorie diet andincreased physical activity for chronic weight management in clinically obeseadults (BMI of 30 kg/m2 or greater) and overweight adults (BMI of 27 kg/m2 orgreater) with at least one weight-related comorbid condition.
Specification
Audited Supplier 
){kind=link}
){kind=link}